SAN DIEGO -- Patients and clinicians looking to mobile applications to support weight loss and heart health goals face a deluge of dubious options. One physician and "mHealth" expert highlighted a handful of the more promising candidates at the American College of Physicians Internal Medicine Meeting here on Friday.
There are an estimated 260,000 mHealth apps as of 2016 -- a 57% increase from 2015, according to Research2Guidance, a consultant for mobile app companies, said Rajesh Patel, MD, MPH, associate chief medical information officer and a hospitalist at Brigham and Women's Hospital in Boston.
But the explosion of mHealth apps is outpacing the research community's ability to vet them, said Patel.
And the means that most of these apps don't fall under the agency's purview, he added. Only apps considered to be an "accessory to a regulated medical device" or those that can transform into such a device (i.e., electronic stethoscopes and glucometers) are evaluated by the agency.
Signs Point to 'No'
Patel said that according to what little research is available on apps that promote weight loss and physical activity, the majority do not leverage evidence-based strategies.
For example, a 2013 study published in the American Journal of Preventive Medicine, which analyzed 30 weight loss apps, including some of the most popular -- LoseIt, LiveStrong, and MyFitnessPal -- found that most such as the ).
A separate study from the Journal of Medical Internet Research published in 2016, which looked at 393 weight loss apps and evaluated them based on (e.g., goal-setting, personalized feedback, and social support) found that only 4% included even half of the strategies.
"Commercial mobile apps for weight loss/management lack important evidence-based features, do not involve healthcare experts in their development process, and have not undergone rigorous scientific testing," the study authors concluded.
But, Patel asked, does using clinician-vetted strategies really matter?
A third study, a meta-analysis of 12 studies of mobile phone apps' impact on weight loss and physical activity, also published in the , found no difference in physical activity, but there was a "significant reduction" in the pooled results for weight loss and BMI over the study period. Yet, the absolute difference in weight loss -- 1.04 kg over a roughly 3-6 month stretch -- and the BMI reduction of 0.43 points did not impress Patel, he said.
Hope for Overweight Patients
But the news is not all bad. Patel also highlighted a study of the Prevent app, published by , which examines the impact of transforming the Diabetes Prevention Program (DPP) into an online social network. The core online program lasted 16 weeks and included four components:
- a peer group matched by age, location, and body mass index
- a coach trained in the DPP curriculum
- a tracking mechanism
- weekly lesson plans
Lessons were divided into monthly phases, and participants received different tools in the mail at the start of each phase, including a pedometer, a digital scale, and a photo frame for motivational purposes. Participants were given the option of continuing a "post-core lifestyle change maintenance intervention," after 16 weeks, bringing the total length of the extended program to 12 months.
Instead of a randomized controlled trial, the study measured the online program against the standards of the Centers for Disease Control and Prevention's Diabetes Prevention and Recognition Program (DPRP) which set a 5.0% weight loss benchmark.
After 16 weeks, 68% of the 187 participants finished the program and hit the 5.0% weight loss benchmark, with most maintaining a 4.8% weight loss after 12 months -- a reduction of about 12.2 and 11.6 pounds, respectively. At the end of both the core and post-care phase of the program, 50% of participants "met or exceeded" the 5.0% weight loss benchmark.
Following the study, the program was commercialized by Omada Health, reportedly the largest app-based CDC-recognized DPP provider.
Curbing Hypertension
Patel also spotlighted another study: a randomized controlled trial of an online intervention for hypertension, published in the
A small study from Massachusetts General Hospital involved 44 patients randomized either to an experimental group using an app known as CollaboRhythm, or to a traditional coaching model. All patients' systolic/diastolic blood pressure was measured over 12 weeks.
The CollaboRhythm app leveraged visualization tools to help patients track their treatments and assess blood pressure measurements at a set time each day. The tools included personalized decision support intended to enhance self-efficacy and encourage patients to make "collaborative decisions," with health coaches offering support.
The traditional coaching model used an integrated care management approach; a nurse educator sent regular follow-up messages by email, text, or phone and arranged visits to assess changes in blood pressure.
The control group of 22 participants saw a drop in systolic pressure (mm Hg) of 16 points, whereas the 20 patients given the intervention witnessed a 26 point reduction in systolic blood pressure.
In addition, 15 (75%) of the intervention participants achieved the goal blood pressure (with systolic blood pressure less than or equal to 130 mm Hg and diastolic less than or equal to 80 mm Hg) whereas seven participants (32%) in the control group achieved the same benchmark.
This study was also commercialized and formed a company, Twine Health in Cambridge, Mass. The mHealth product is accessible through health plans, and employer health systems as well as direct primary care providers and will soon be free for individual patients, Patel said.
The same health activation program is also being used for other diseases such as diabetes and depression.
Diabetes
Lastly, Patel spoke of a that examined a mobile app for glucose control.
The study, published by Diabetes Care in 2011, randomized 26 primary care practices to one of four groups:
- usual care
- coaching app, offering real-time advice and allowing data entry
- coaching app, with a primary care provider portal (including secure messages, a learning library, and historical data)
- coaching app, plus a primary care provider portal and clinical decision support
The second group received real-time coaching. The third group with access to a primary care provider portal had only data views of their entries, but no analytics, while the fourth group received advice on medication management based on the patient's analytics compared with certain guidelines.
The researchers assessed the impact on 163 patients with poor diabetes control (baseline A1c = 9.4) and then evaluated the program's impact after 12 months.
Those in the fourth group receiving the comprehensive package of support saw a decrease in mean A1c values of 1.9 over 12 months with those in the "usual care" group seeing only a mean reduction of 0.7%.
This program was also commercialized by WellDoc/BlueStar. It is FDA-approved and available by prescription.
Disclosures
Patel reported no financial or other disclosures.